Experts say no inhaler suits every patient with chronic obstructive pulmonary disease, and technique can fade within 30 days without retraining.
|Articles|February 25, 2022
AJMC® in the Press, February 25, 2022
Author(s)AJMC Staff
Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.
Advertisement
An article by
Advertisement
Related to this article
Experts say COPD care should aim for disease stability, with advanced therapy a routine next step, not a last resort, for patients who fall short.
Antimicrobial resistance in bronchiectasis and cystic fibrosis varied widely in a study spanning 11 centers on 3 continents.
The EEOC is reportedly preparing to narrow Pregnant Workers Fairness Act rules; no revised rule has been published as of yet.
Experts break down the GOLD 2026 COPD guidelines, highlighting updates to diagnosis criteria, Group E risk categories, and nonpharmacologic interventions.
An economic evaluation found nontargeted hepatitis C screening in emergency departments offered the greatest health benefit at a cost-effective price.
Pooled data on 2698 patients tie rituximab maintenance after bendamustine-rituximab to better PFS and OS in mantle cell lymphoma.
Among 788 patch-tested patients with hand eczema in Shanghai, 82% reacted to at least 1 allergen.
Advertisement
Advertisement
Trending on AJMC
1
Acoramidis Linked to Fewer Hospitalizations Than Tafamidis in ATTR-CM
2
NYC Marathon Death Puts Rhabdomyolysis Risk Factors in Focus
3
EEOC Reportedly Plans to Narrow Pregnancy Accommodation Rules
4
Real-World Evidence, Rare Liver Disease Data Headline Kidney Week 2026
5